JPRN-UMIN000012724尚未招募未知
The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to Aflibercept - The switching therapy with Ranibizumab for Exudative Age-related Macular Degeneration resistant to Aflibercept
Department of Ophthalmology, Kagawa university faculty of medicine0 个研究点目标入组 30 人开始时间: 2013年12月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2)Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3)Prior treatment with photodynamic therapy 4)Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5)Active intraocular inflammation 6)Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7)Patient who the doctor in charge judges are ineligible for the study
研究者
相似试验
进行中（未招募）
1 期
The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation - Management and control of corneal neovascularisation using LucentisCorneal neovesselsEUCTR2010-018673-37-GBniversity of Nottingham6
尚未招募
不适用
Establishment of a proper use of ranibizumab for the macular edema in retinal vein occlusioRetinal vein occlusionJPRN-UMIN000012188Departmant of opthalmology,Kansai Medical University50
招募中
2 期
A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.Diabetic Macular OedemaEye - Diseases / disorders of the eyeMetabolic and Endocrine - DiabetesDiabetic RetinopathyACTRN12611000063910ovartis40
已完成
不适用
Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema.diabetic macular edemaJPRN-UMIN000024697Tokyo Women's Medical University100
进行中（未招募）
1 期
Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusionA randomized, controlled interventional phase 2b (proof of concept) study of of the efficacy, safety, and tolerability of repeated intravitreal administration of ranibizumab combined with selective laser photocoagulation of non-perfused retinal areas in subjects with macular edema secondary to central retinal vein occlusion (CRVO)macular edema secondary to non-ischemic central retinal vein occlusionMedDRA version: 14.0Level: LLTClassification code 10054467Term: Macular edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: LLTClassification code 10007972Term: Central retinal vein occlusionSystem Organ Class: 10015919 - Eye disordersEUCTR2010-020441-27-DEniversity of Leipzig Ritterstr. 26, 04109 Leipzig